DiaMedica provides DM199 preeclampsia update after FDA pre-IND meeting; additional rabbit study required

DiaMedica Therapeutics Inc.

FDA requested one non-clinical 10-day rabbit EFD/PPND study; results expected by Q2 2026.
Phase 2 investigator-sponsored trial in South Africa has dosed over 30 women with late-stage PE.
Interim data: statistically significant blood pressure reductions, uterine artery dilation, no placental transfer.
Regulatory clarity obtained for IND submission to study DM199 in early-onset preeclampsia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.